-
1
-
-
0041475779
-
Neuroblastoma: biology and molecular and chromosomal pathology
-
Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 2003; 4:472-480.
-
(2003)
Lancet Oncol
, vol.4
, pp. 472-480
-
-
Schwab, M.1
Westermann, F.2
Hero, B.3
Berthold, F.4
-
3
-
-
0023260866
-
Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients
-
Brodeur GM, Hayes FA, Green AA, Casper JT, Wasson J, Wallach S, Seeger RC. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res. 1987; 47:4248-4253.
-
(1987)
Cancer Res
, vol.47
, pp. 4248-4253
-
-
Brodeur, G.M.1
Hayes, F.A.2
Green, A.A.3
Casper, J.T.4
Wasson, J.5
Wallach, S.6
Seeger, R.C.7
-
4
-
-
0022575467
-
Gene amplification in human neuroblastomas: basic mechanisms and clinical implications
-
Brodeur GM, Seeger RC. Gene amplification in human neuroblastomas: basic mechanisms and clinical implications. Cancer Genet Cytogenet. 1986; 19:101-111.
-
(1986)
Cancer Genet Cytogenet
, vol.19
, pp. 101-111
-
-
Brodeur, G.M.1
Seeger, R.C.2
-
5
-
-
0021261878
-
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
-
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224:1121-1124.
-
(1984)
Science
, vol.224
, pp. 1121-1124
-
-
Brodeur, G.M.1
Seeger, R.C.2
Schwab, M.3
Varmus, H.E.4
Bishop, J.M.5
-
6
-
-
0022388606
-
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
-
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313:1111-1116.
-
(1985)
N Engl J Med
, vol.313
, pp. 1111-1116
-
-
Seeger, R.C.1
Brodeur, G.M.2
Sather, H.3
Dalton, A.4
Siegel, S.E.5
Wong, K.Y.6
Hammond, D.7
-
7
-
-
0033987789
-
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study
-
Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol. 2000; 18:18-26.
-
(2000)
J Clin Oncol
, vol.18
, pp. 18-26
-
-
Perez, C.A.1
Matthay, K.K.2
Atkinson, J.B.3
Seeger, R.C.4
Shimada, H.5
Haase, G.M.6
Stram, D.O.7
Gerbing, R.B.8
Lukens, J.N.9
-
8
-
-
0028796681
-
Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study
-
Cohn SL, Look AT, Joshi VV, Holbrook T, Salwen H, Chagnovich D, Chesler L, Rowe ST, Valentine MB, Komuro H, et al. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cancer Res. 1995; 55:721-726.
-
(1995)
Cancer Res
, vol.55
, pp. 721-726
-
-
Cohn, S.L.1
Look, A.T.2
Joshi, V.V.3
Holbrook, T.4
Salwen, H.5
Chagnovich, D.6
Chesler, L.7
Rowe, S.T.8
Valentine, M.B.9
Komuro, H.10
-
9
-
-
0031749828
-
Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study
-
Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, Look AT, Rowe ST, Nash MB, Holbrook T, Alvarado C, Rao PV, Castleberry RP, Cohn SL. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. J Clin Oncol. 1998; 16:2007-2017.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2007-2017
-
-
Katzenstein, H.M.1
Bowman, L.C.2
Brodeur, G.M.3
Thorner, P.S.4
Joshi, V.V.5
Smith, E.I.6
Look, A.T.7
Rowe, S.T.8
Nash, M.B.9
Holbrook, T.10
Alvarado, C.11
Rao, P.V.12
Castleberry, R.P.13
Cohn, S.L.14
-
10
-
-
0033120488
-
Differentiation and apoptosis of neuroblastoma cells: role of N-myc gene product
-
Galderisi U, Di Bernardo G, Cipollaro M, Peluso G, Cascino A, Cotrufo R, Melone MA. Differentiation and apoptosis of neuroblastoma cells: role of N-myc gene product. J Cell Biochem. 1999; 73:97-105.
-
(1999)
J Cell Biochem
, vol.73
, pp. 97-105
-
-
Galderisi, U.1
Di Bernardo, G.2
Cipollaro, M.3
Peluso, G.4
Cascino, A.5
Cotrufo, R.6
Melone, M.A.7
-
11
-
-
56749184298
-
Reflecting on 25 years with MYC
-
Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8:976-990.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 976-990
-
-
Meyer, N.1
Penn, L.Z.2
-
12
-
-
0021276218
-
Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc
-
Schwab M, Varmus HE, Bishop JM, Grzeschik KH, Naylor SL, Sakaguchi AY, Brodeur G, Trent J. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature. 1984; 308:288-291.
-
(1984)
Nature
, vol.308
, pp. 288-291
-
-
Schwab, M.1
Varmus, H.E.2
Bishop, J.M.3
Grzeschik, K.H.4
Naylor, S.L.5
Sakaguchi, A.Y.6
Brodeur, G.7
Trent, J.8
-
13
-
-
0024441031
-
Molecular biology and genetics of human neuroblastoma
-
Brodeur GM, Fong CT. Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet. 1989; 41:153-174.
-
(1989)
Cancer Genet Cytogenet
, vol.41
, pp. 153-174
-
-
Brodeur, G.M.1
Fong, C.T.2
-
14
-
-
0028305310
-
MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells
-
Corvi R, Amler LC, Savelyeva L, Gehring M, Schwab M. MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells. Proc Natl Acad Sci U S A. 1994; 91:5523-5527.
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, pp. 5523-5527
-
-
Corvi, R.1
Amler, L.C.2
Savelyeva, L.3
Gehring, M.4
Schwab, M.5
-
15
-
-
0026463651
-
Isolation and structural analysis of a 1 2-megabase N-myc amplicon from a human neuroblastoma
-
Schneider SS, Hiemstra JL, Zehnbauer BA, Taillon-Miller P, Le Paslier DL, Vogelstein B, Brodeur GM. Isolation and structural analysis of a 1.2-megabase N-myc amplicon from a human neuroblastoma. Mol Cell Biol. 1992; 12:5563-5570.
-
(1992)
Mol Cell Biol
, vol.12
, pp. 5563-5570
-
-
Schneider, S.S.1
Hiemstra, J.L.2
Zehnbauer, B.A.3
Taillon-Miller, P.4
Le Paslier, D.L.5
Vogelstein, B.6
Brodeur, G.M.7
-
16
-
-
0026844368
-
Myb: a transcriptional activator linking proliferation and differentiation in hematopoietic cells
-
Graf T. Myb: a transcriptional activator linking proliferation and differentiation in hematopoietic cells. Curr Opin Genet Dev. 1992; 2:249-255.
-
(1992)
Curr Opin Genet Dev
, vol.2
, pp. 249-255
-
-
Graf, T.1
-
17
-
-
0024269499
-
Isolation of human cDNA clones of myb-related genes A-myb and B-myb
-
Nomura N, Takahashi M, Matsui M, Ishii S, Date T, Sasamoto S, Ishizaki R. Isolation of human cDNA clones of myb-related genes, A-myb and B-myb. Nucleic Acids Res. 1988; 16:11075-11089.
-
(1988)
Nucleic Acids Res
, vol.16
, pp. 11075-11089
-
-
Nomura, N.1
Takahashi, M.2
Matsui, M.3
Ishii, S.4
Date, T.5
Sasamoto, S.6
Ishizaki, R.7
-
18
-
-
0000257239
-
Delineation of three functional domains of the transcriptional activator encoded by the c-myb protooncogene
-
Sakura H, Kanei-Ishii C, Nagase T, Nakagoshi H, Gonda TJ, Ishii S. Delineation of three functional domains of the transcriptional activator encoded by the c-myb protooncogene. Proc Natl Acad Sci U S A. 1989; 86:5758-5762.
-
(1989)
Proc Natl Acad Sci U S A
, vol.86
, pp. 5758-5762
-
-
Sakura, H.1
Kanei-Ishii, C.2
Nagase, T.3
Nakagoshi, H.4
Gonda, T.J.5
Ishii, S.6
-
19
-
-
0027190042
-
Functional domains of the human B-myb gene product
-
Nakagoshi H, Takemoto Y, Ishii S. Functional domains of the human B-myb gene product. J Biol Chem. 1993; 268:14161-14167.
-
(1993)
J Biol Chem
, vol.268
, pp. 14161-14167
-
-
Nakagoshi, H.1
Takemoto, Y.2
Ishii, S.3
-
20
-
-
0026083897
-
Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells
-
Golay J, Capucci A, Arsura M, Castellano M, Rizzo V, Introna M. Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells. Blood. 1991; 77:149-158.
-
(1991)
Blood
, vol.77
, pp. 149-158
-
-
Golay, J.1
Capucci, A.2
Arsura, M.3
Castellano, M.4
Rizzo, V.5
Introna, M.6
-
21
-
-
0025941870
-
Growth regulated expression of B-myb in fibroblasts and hematopoietic cells
-
Reiss K, Travali S, Calabretta B, Baserga R. Growth regulated expression of B-myb in fibroblasts and hematopoietic cells. J Cell Physiol. 1991; 148:338-343.
-
(1991)
J Cell Physiol
, vol.148
, pp. 338-343
-
-
Reiss, K.1
Travali, S.2
Calabretta, B.3
Baserga, R.4
-
22
-
-
0026783836
-
Characterization and cell cycle-regulated expression of mouse B-myb
-
Lam EW, Robinson C, Watson RJ. Characterization and cell cycle-regulated expression of mouse B-myb. Oncogene. 1992; 7:1885-1890.
-
(1992)
Oncogene
, vol.7
, pp. 1885-1890
-
-
Lam, E.W.1
Robinson, C.2
Watson, R.J.3
-
24
-
-
0033214067
-
B-myb is required for inner cell mass formation at an early stage of development
-
Tanaka Y, Patestos NP, Maekawa T, Ishii S. B-myb is required for inner cell mass formation at an early stage of development. J Biol Chem. 1999; 274:28067-28070.
-
(1999)
J Biol Chem
, vol.274
, pp. 28067-28070
-
-
Tanaka, Y.1
Patestos, N.P.2
Maekawa, T.3
Ishii, S.4
-
25
-
-
0026632658
-
B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines
-
Arsura M, Introna M, Passerini F, Mantovani A, Golay J. B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines. Blood. 1992; 79:2708-2716.
-
(1992)
Blood
, vol.79
, pp. 2708-2716
-
-
Arsura, M.1
Introna, M.2
Passerini, F.3
Mantovani, A.4
Golay, J.5
-
26
-
-
0026469084
-
Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression
-
Sala A, Calabretta B. Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression. Proc Natl Acad Sci U S A. 1992; 89:10415-10419.
-
(1992)
Proc Natl Acad Sci U S A
, vol.89
, pp. 10415-10419
-
-
Sala, A.1
Calabretta, B.2
-
27
-
-
0030070757
-
B-Myb prevents growth arrest associated with terminal differentiation of monocytic cells
-
Bies J, Hoffman B, Amanullah A, Giese T, Wolff L. B-Myb prevents growth arrest associated with terminal differentiation of monocytic cells. Oncogene. 1996; 12:355-363.
-
(1996)
Oncogene
, vol.12
, pp. 355-363
-
-
Bies, J.1
Hoffman, B.2
Amanullah, A.3
Giese, T.4
Wolff, L.5
-
28
-
-
80051701028
-
Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop
-
Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschella G, Sala A. Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. Oncotarget. 2010; 1:278-288.
-
(2010)
Oncotarget
, vol.1
, pp. 278-288
-
-
Gualdrini, F.1
Corvetta, D.2
Cantilena, S.3
Chayka, O.4
Tanno, B.5
Raschella, G.6
Sala, A.7
-
29
-
-
0027104314
-
Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship
-
Fosse P, Rene B, Charra M, Paoletti C, Saucier JM. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship. Mol Pharmacol. 1992; 42:590-595.
-
(1992)
Mol Pharmacol
, vol.42
, pp. 590-595
-
-
Fosse, P.1
Rene, B.2
Charra, M.3
Paoletti, C.4
Saucier, J.M.5
-
30
-
-
0026011643
-
DNA-drug recognition and effects on topoisomerase IImediated cytotoxicity A three-mode binding model for ellipticine derivatives
-
Monnot M, Mauffret O, Simon V, Lescot E, Psaume B, Saucier JM, Charra M, Belehradek J, Jr., Fermandjian S. DNA-drug recognition and effects on topoisomerase IImediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem. 1991; 266:1820-1829.
-
(1991)
J Biol Chem
, vol.266
, pp. 1820-1829
-
-
Monnot, M.1
Mauffret, O.2
Simon, V.3
Lescot, E.4
Psaume, B.5
Saucier, J.M.6
Charra, M.7
Belehradek Jr., J.8
Fermandjian, S.9
-
31
-
-
0029015354
-
Topoisomerase II binds to ellipticine in the absence or presence of DNA Characterization of enzyme-drug interactions by fluorescence spectroscopy
-
Froelich-Ammon SJ, Patchan MW, Osheroff N, Thompson RB. Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem. 1995; 270:14998-15004.
-
(1995)
J Biol Chem
, vol.270
, pp. 14998-15004
-
-
Froelich-Ammon, S.J.1
Patchan, M.W.2
Osheroff, N.3
Thompson, R.B.4
-
32
-
-
0032189683
-
Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
-
Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta. 1998; 1400:83-105.
-
(1998)
Biochim Biophys Acta
, vol.1400
, pp. 83-105
-
-
Pommier, Y.1
Pourquier, P.2
Fan, Y.3
Strumberg, D.4
-
33
-
-
0035029153
-
Tumor cell death induced by topoisomerasetargeting drugs
-
Li TK, Liu LF. Tumor cell death induced by topoisomerasetargeting drugs. Annu Rev Pharmacol Toxicol. 2001; 41:53-77.
-
(2001)
Annu Rev Pharmacol Toxicol
, vol.41
, pp. 53-77
-
-
Li, T.K.1
Liu, L.F.2
-
34
-
-
0037180432
-
The mechanism of topoisomerase I poisoning by a camptothecin analog
-
Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Jr., Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A. 2002; 99:15387-15392.
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 15387-15392
-
-
Staker, B.L.1
Hjerrild, K.2
Feese, M.D.3
Behnke, C.A.4
Burgin Jr., A.B.5
Stewart, L.6
-
35
-
-
22744438407
-
Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis
-
Ioanoviciu A, Antony S, Pommier Y, Staker BL, Stewart L, Cushman M. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J Med Chem. 2005; 48:4803-4814.
-
(2005)
J Med Chem
, vol.48
, pp. 4803-4814
-
-
Ioanoviciu, A.1
Antony, S.2
Pommier, Y.3
Staker, B.L.4
Stewart, L.5
Cushman, M.6
-
36
-
-
0030826233
-
A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons
-
Capranico G, Binaschi M, Borgnetto ME, Zunino F, Palumbo M. A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends Pharmacol Sci. 1997; 18:323-329.
-
(1997)
Trends Pharmacol Sci
, vol.18
, pp. 323-329
-
-
Capranico, G.1
Binaschi, M.2
Borgnetto, M.E.3
Zunino, F.4
Palumbo, M.5
-
37
-
-
0031759531
-
Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study
-
Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 1998; 20:315-318.
-
(1998)
J Pediatr Hematol Oncol
, vol.20
, pp. 315-318
-
-
Nitschke, R.1
Parkhurst, J.2
Sullivan, J.3
Harris, M.B.4
Bernstein, M.5
Pratt, C.6
-
38
-
-
0034688264
-
Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation
-
De Falco G, Bagella L, Claudio PP, De Luca A, Fu Y, Calabretta B, Sala A, Giordano A. Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation. Oncogene. 2000; 19:373-379.
-
(2000)
Oncogene
, vol.19
, pp. 373-379
-
-
De Falco, G.1
Bagella, L.2
Claudio, P.P.3
De Luca, A.4
Fu, Y.5
Calabretta, B.6
Sala, A.7
Giordano, A.8
-
39
-
-
0021683414
-
Human neuroblastomas and abnormalities of chromosomes 1 and 17
-
Gilbert F, Feder M, Balaban G, Brangman D, Lurie DK, Podolsky R, Rinaldt V, Vinikoor N, Weisband J. Human neuroblastomas and abnormalities of chromosomes 1 and Cancer Res. 1984; 44:5444-5449.
-
(1984)
Cancer Res
, vol.44
, pp. 5444-5449
-
-
Gilbert, F.1
Feder, M.2
Balaban, G.3
Brangman, D.4
Lurie, D.K.5
Podolsky, R.6
Rinaldt, V.7
Vinikoor, N.8
Weisband, J.9
-
40
-
-
65949108394
-
B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells
-
Mannefeld M, Klassen E, Gaubatz S. B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells. Cancer Res. 2009; 69:4073-4080.
-
(2009)
Cancer Res
, vol.69
, pp. 4073-4080
-
-
Mannefeld, M.1
Klassen, E.2
Gaubatz, S.3
-
42
-
-
18144444652
-
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology
-
Vassal G, Pondarre C, Boland I, Cappelli C, Santos A, Thomas C, Lucchi E, Imadalou K, Pein F, Morizet J, Gouyette A. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie. 1998; 80:271-280.
-
(1998)
Biochimie
, vol.80
, pp. 271-280
-
-
Vassal, G.1
Pondarre, C.2
Boland, I.3
Cappelli, C.4
Santos, A.5
Thomas, C.6
Lucchi, E.7
Imadalou, K.8
Pein, F.9
Morizet, J.10
Gouyette, A.11
-
43
-
-
0042912912
-
Clinical and cellular pharmacology in relation to solid tumours of childhood
-
Estlin EJ, Veal GJ. Clinical and cellular pharmacology in relation to solid tumours of childhood. Cancer Treat Rev. 2003; 29:253-273.
-
(2003)
Cancer Treat Rev
, vol.29
, pp. 253-273
-
-
Estlin, E.J.1
Veal, G.J.2
-
44
-
-
79960930191
-
Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors
-
Mairs RJ, Boyd M. Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors. Semin Nucl Med. 2011; 41:334-344.
-
(2011)
Semin Nucl Med
, vol.41
, pp. 334-344
-
-
Mairs, R.J.1
Boyd, M.2
-
45
-
-
34247541700
-
Targeting an E2F site in the mouse genome prevents promoter silencing in quiescent and post-mitotic cells
-
Tavner F, Frampton J, Watson RJ. Targeting an E2F site in the mouse genome prevents promoter silencing in quiescent and post-mitotic cells. Oncogene. 2007; 26:2727-2735.
-
(2007)
Oncogene
, vol.26
, pp. 2727-2735
-
-
Tavner, F.1
Frampton, J.2
Watson, R.J.3
|